Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cobra Biologics and BioCancell Announce Agreement

Published: Tuesday, March 04, 2014
Last Updated: Tuesday, March 04, 2014
Bookmark and Share
Agreement to manufacture promising cancer therapy drug.

Cobra Biologics and BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.

BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuity of the success of pre-clinical studies that examined the use of BC-821 as a treatment for several cancer indications such as Non-small-cell lung carcinoma, Ovarian cancer, Glioblastoma (brain tumour) and Liver metastasis.

Cobra will provide GMP manufacture of BC-821 plasmid DNA, and fill and finish the product in accordance with aseptic manufacturing procedures before releasing it for clinical trials.

Cobra’s experienced and expert team have a strong track record for producing non-GMP, high quality, and GMP plasmid DNA for preclinical, clinical and commercial supply, operating efficiently and consistently through a platform DNA process. Cobra’s DNA programs have full regulatory support from a dedicated Quality Assurance (QA) team.

BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA under the control of H19 and /or P4 promoter of the target gene IGF2. Both H19 and P4-IGF2 transcription factors are expressed only in cancerous cells.

This double-promoter method has the potential to reach a large patient population, as patients expressing either of the target genes will be treatable. An international patent application (PCT) for this product was filed by BioCancell in 2008.

Peter Coleman, CEO Cobra Biologics commented: “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 16 years and I am delighted that we are able to announce this partnership with BioCancell. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics Develop Special Cell Line for Alligator Bioscience
The cell line designed expresses monoclonal antibodies that have been vital for the success of a clinical trial ran by Alligator Biosciences.
Thursday, May 28, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics Granted Approval for Research Tax Credit
Company has recognized as an approved service provider for the period 2013 to 2015.
Wednesday, April 02, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Novolytics Develop Bacteriophages Against Infection
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.
Wednesday, June 12, 2013
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
New contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate program.
Tuesday, January 15, 2013
Cobra Biologics’ Growth is Strengthened
A new non-executive director joins Cobra’s board to support expansion plans.
Tuesday, October 23, 2012
Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
Agreement for the production of monoclonal antibody drug substance and drug product for pre-clinical studies and Phase I-II clinical trials.
Tuesday, June 19, 2012
Cobra Biologics’ Expansion Continues
Appointment of three non-executive directors and two business development managers to Cobra Biologics’ board.
Tuesday, February 14, 2012
Cobra Biologics Acquires Unitech Pharma Group
Acquisition to expand Cobra’s capacity and biopharmaceutical service offering.
Tuesday, November 01, 2011
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos